1,720,990 research outputs found
Stability of the chemical xenogenization inducer, MM-COOK, possible metabolite of the antimetastatic agent, DM-COOK. A kinetic investigation.
No full text
Simultaneous determination of ionization constant and partition coefficient of DM-COOK, a potent antimetastatic agent.
No full textProphylactic antimetastatic treatment with aryldimethyltriazenes as adjuvants to surgical tumor removal in mice bearing Lewis lung carcinoma.
No full textThe effects of two benzenoid dimethyltriazenes (1-p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt [DM-COOK] and 1-p-tolyl-3,3-dimethyltriazene), which have been previously shown to reduce the formation of spontaneous lung metastases in mice bearing subcutaneous Lewis lung carcinoma, have been investigated in mice implanted im with the same tumor in the calf of the hind leg. Primary tumor was removed surgically by amputation in mice treated with the tested compounds preoperatively, and the survival time of the animals was then determined. A high rate of cures, ranging from 23\% to 43\%, has been observed when the treatment consisted of eight or three daily doses prior to tumor removal; a single immediately preoperative dose was less effective and caused a 10\% cure rate. Survival time of uncured mice was also significantly increased, particularly by DM-COOK. The division of the dose into two daily injections did not modify the activity of the triazenes, thus indicating that the antimetastatic coverage between two subsequent doses is not limited by fast pharmacokinetics or decomposition of the drugs. These results show that, at least in one animal system, aryldimethyltriazenes can be used also on palpable tumors as prophylactic adjuvants to surgery in order to reduce preoperative and intraoperative tumor spread
Synthesis of 1-aryl-3-formyl-3-methyltriazenes, potential metabolites of 1-aryl-3,3-dimethyltriazenes.
No full textSome para-substituted 1-aryl-3,3-dimethyltriazenes were oxidized with tert-butyl hydroperoxide in the presence of vanadium pentoxide as a catalyst. Under these conditions, the corresponding 1-aryl-3-formyl-3-methyltriazenes, 1-aryl-3-tert-butylperoxymethyl-3-methyltriazenes, and p-nitrobenzenes were obtained. The 1-aryl-3-formyl-3-methyltriazenes might play a role in the metabolic oxidation of the 1-aryl-3,3-dimethyltriazenes, which are active as mutagenic, carcinogenic, and antitumor agents
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Metabolism and mechanism of the antileukemic action of isomeric aryldimethyltriazenes.
No full textMice bearing TLX5 lymphoma or P388 leukemia were treated with ortho, meta, and para isomers of the salts of (3,3-dimethyl-1-triazeno)benzoic acid. Survival time was markedly increased in mice given the para isomer; effects were less pronounced for the meta isomer and absent for the ortho isomer. The in vivo effects of the tested compounds did not correlate either with the propensity of the drugs to undergo oxidative N-demethylation and hydrolysis to diazonium cations or with in vitro cytotoxicity for TLX5 lymphoma cells. The para isomer did not reduce the number and viability of peritoneal TLX5 lymphoma cells after in vivo and in vitro treatment, whereas a dose-dependent reduction that can even result in the absence of clonogenic tumor cells occurred in the brains of the treated animals. These data indicate that the increased survival time of the tumor-bearing mice treated with the para isomer should not be ascribed to cytotoxic effects of the drug and might be attributed to inhibition of tumor cell dissemination in various organs of the host, as already observed for solid metastasizing tumors in mice
- …
